Tag Archives: melbourne

Eighty percent of bowel cancers halted with existing medicines

The study found that medicines called ‘JAK inhibitors’ halted tumour growth in bowel cancers with a genetic mutation that is present in more than 80 per cent of bowel cancers. Multiple JAK inhibitors are currently used, or are in clinical trials, for diseases including rheumatoid arthritis, psoriasis, blood cancers and myeloproliferative disorders. Bowel cancer is the second-most common cancer in Australia with nearly 17,000 people diagnosed every year, accounting for almost one out of 10 cancer-related deaths. Dr Toby Phesse, Dr Michael Buchert, Associate Professor Matthias Ernst and colleagues from Melbourne’s Walter and Eliza Hall Institute, in collaboration with Australian and international researchers, commenced the study while at the Melbourne-Parkville branch of the Ludwig Institute for Cancer Research…

Researchers unlock genetic code of cancer-causing liver fluke parasite

GIS’s DNA analysistechnique has allowed the researchers to further study the biology of Opisthorchis viverrini to understand the cause and the eventual development of treatments for bile duct cancer, a condition caused by the parasite. The breakthrough was published in the scientific journal Nature Communications. Opisthorchis viverrini is a trematode that infects millions in Asia, and it is classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC). …

New ways to treat solid tumors using protein — ScienceDaily

As EphA3 is present in normal organs only during embryonic development but is expressed in blood cancers and in solid tumors, this antibody-based approach may be a suitable candidate treatment for solid tumors. The researchers from Monash University and Ludwig Cancer Research, in Australia, and KaloBios Pharmaceuticals, in the US, have had their findings published in the journal Cancer Research. The team, led jointly by the late Professor Martin Lackmann, from the School of Biomedical Sciences at Monash; and Professor Andrew Scott, from Ludwig Cancer Research, has found that even if tumor cells do not have this molecule they can thrive by recruiting and taking advantage of supporting EphA3-containing cells in the tumor micro-environment…

New ways to treat solid tumors using protein

As EphA3 is present in normal organs only during embryonic development but is expressed in blood cancers and in solid tumors, this antibody-based approach may be a suitable candidate treatment for solid tumors. The researchers from Monash University and Ludwig Cancer Research, in Australia, and KaloBios Pharmaceuticals, in the US, have had their findings published in the journal Cancer Research…